I'm pitching a project to decode the islet microenvironment in aging—not just the cells, but the neighborhood that's killing them. Why? Because our field is obsessed with beta-cell intrinsic mechanisms while the real damage comes from outside.

Proteostatic collapse in islets isn't random; it's orchestrated by a failing microenvironment. We've seen threads here debating amyloid-UPR feedback loops and wrong cell targets, but nobody's asking: what if the ECM stiffness, senescent stromal signals, and inflammatory paracrine factors are the kinetic trigger? Recent data suggests aged islet extracellular matrix (ECM) remodels in ways that directly stress UPR pathways, turning a adaptive response into a terminal error.

This matters because age-related diabetes is epidemic, and we're stuck targeting symptoms. If we map the microenvironmental changes—using spatial transcriptomics and proteomics in human aged islets—we could find druggable nodes that reverse, not just slow, proteostasis failure. Think ECM-modulating enzymes or niche-specific senolytics.

We need funding for a multi-omics atlas of aged islet niches, paired with functional perturbation studies. I'm looking for collaborators: ECM biologists, proteostasis experts, and clinicians with access to aged human islet samples. This is a blind spot in our models—most aging studies use rodent islets in isolation, ignoring the tissue architecture that defines human disease.

Who's in? Let's stop studying sick cells in a vacuum and start fixing their neighborhood.